10-Q · May 12, 2026
Cyclerion Therapeutics (CYCN) reported a significant decline in revenues in Q1 2026, with total revenue dropping to $0 compared to $81,000 in Q1 2025. The company continues to incur substantial losses, posting a net…
Earnings analysis · 10-Q
CYCN earnings analysis
Filed August 4, 2026 · Our reading of the company's report
The latest report
Cyclerion reported no Q2 2026 revenue, versus $93,000 a year earlier, and a $1.755 million net loss; the loss narrowed materially from Q1 but deteriorated sharply versus Q2 2025. First-half operating cash use rose to…
Read full summary
Cyclerion reported no Q2 2026 revenue, versus $93,000 a year earlier, and a $1.755 million net loss; the loss narrowed materially from Q1 but deteriorated sharply versus Q2 2025. First-half operating cash use rose to $2.608 million and cash ended June at only approximately $1.4 million, leading management to retain a going-concern conclusion. The investment case is overwhelmingly contingent on closing the anticipated Q3 2026 Korsana merger and its approximately $380.0 million concurrent financing; no stand-alone financial guidance was provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Segment
- Revenue from option agreement: $0 in Q2 2026, versus $93,000 in Q2 2025.
What stood out
-
Revenue remained at zero
Q2 revenue was $0, unchanged sequentially from Q1 2026's $0 but down $93,000, or 100%, from Q2 2025. The only reported revenue stream, the olinciguat option agreement, was terminated in October 2025.
-
Sequential loss narrowed, year-over-year worsened
The Q2 operating loss was $1.771 million, improving by $1.438 million from an implied $3.209 million in Q1 2026, but worsening by $99,000 from a $1.672 million loss in Q2 2025. Gross and operating margins are not meaningful on $0 revenue, and Q2 EPS was not disclosed in the extracted filing.
-
Net loss improved sequentially
Net loss was $1.755 million in Q2, an improvement of $1.422 million from an implied Q1 2026 net loss of $3.177 million, but $1.431 million worse than the $324,000 loss in Q2 2025. Q2 general and administrative expense rose to $1.771 million from $1.709 million, mainly reflecting approximately $0.4 million of higher corporate legal fees.
-
Cash burn accelerated in first half
For the first six months, operating cash outflow increased to $2.608 million from $1.471 million a year earlier. After $66,000 of lab-equipment purchases, derived free cash flow was negative $2.674 million; capex equaled 2.5% of operating cash outflow but cannot be measured against $0 revenue.
-
Low cash supported by working capital
Cash and cash equivalents were approximately $1.4 million at June 30, 2026. Working-capital movements partly offset the $4.932 million six-month loss, including a $1.0 million decline in receivables, a $0.3 million decline in prepaids, and a $1.1 million increase in accounts payable.
-
Merger is the central strategic catalyst
Cyclerion anticipates closing its Korsana merger in Q3 2026. The related pre-closing financing is expected to raise approximately $380.0 million immediately before closing, while the estimated exchange ratio is approximately 1.4735 Cyclerion shares per Korsana common or Series A preferred share, subject to net-cash adjustment and reverse split.
What to watch
-
Going-concern risk remains acute
Management concluded substantial doubt exists about continuing as a going concern: unrestricted cash was approximately $1.4 million at June 30, 2026, the six-month net loss was $4.932 million, and accumulated deficit reached $276.0 million. The company says it would need additional funding if the merger does not close.
-
Merger completion is critical
The company expects cash to last only through the anticipated Q3 2026 merger closing. If the merger and concurrent approximately $380.0 million financing are not consummated, Cyclerion states it may cease operations and seek dissolution if it cannot raise capital.
-
No operating revenue and suspended development
Revenue fell 100% year over year to $0 in Q2 2026 after the option agreement generated $93,000 in Q2 2025 and was terminated in October 2025. Efforts to advance the TRD program have also been suspended because of cash limitations.
-
Funding options are constrained and dilutive
Liquidity remains dependent on equity issuance: the company received $0.8 million of net ATM proceeds in the first half from 405,000 shares sold on January 6, 2026, and had exhausted its available ATM capacity under the applicable Form S-3 limitation during Q1. Future equity financing could materially dilute holders if the merger fails.
-
No new risk-factor updates reported
Item 1A states there were no material changes to risk factors since the March 31, 2026 10-Q. The principal disclosed risks therefore remain cash runway of approximately $1.4 million, a $4.932 million six-month loss, and dependence on a Q3 2026 merger closing.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management anticipates the Korsana merger will close in Q3 2026, subject to shareholder approvals, other closing conditions, and the concurrent approximately $380.0 million Korsana pre-closing financing; Cyclerion expects its June 30 cash balance to fund operations only through the anticipated closing.
Earlier filings 2
10-K · April 30, 2026
Cyclerion Therapeutics (CYCN) in its 2026 10-K filing highlights its strategic merger with Korsana Biosciences aimed at advancing its Alzheimer’s pipeline, promising a stronger competitive positioning in the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.